Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy
- 7 November 2013
- journal article
- review article
- Published by Wiley in IUBMB Life
- Vol. 65 (11), 904-910
- https://doi.org/10.1002/iub.1216
Abstract
One of the principal biochemical characteristics of malignant cells compared to normal cells is a metabolic switch from oxidative phosphorylation to increased glycolysis, even under hypoxic conditions, and is termed the Warburg effect. Lactate dehydrogenase A (LDHA) catalyzes the conversion of pyruvate to lactate and is considered to be a key checkpoint of anaerobic glycolysis. It is elevated in many types of cancers and has been linked to tumor growth, maintenance, and invasion; therefore, its inhibition may restrict the energy supply in tumors and thereby reduce the metastatic and invasive potential of cancer cells. This enzyme is receiving a great deal of attention as a potential diagnostic marker or a predictive biomarker for many types of cancer and as a therapeutic target for new anticancer treatments. In this review, we summarize the role of LDHA in cancer, discuss its potential significance in clinical diagnosis and prognosis of cancer, and propose LDHA as a novel target for the inhibition of tumor growth and invasiveness. © 2013 IUBMB Life, 65(11):904–910, 2013Keywords
Funding Information
- Natural Science Foundation of China (81071180)
- New Drug Discovery Project (2012ZX09506-001-005)
- �973”Project (2012CB932604)
This publication has 47 references indexed in Scilit:
- AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In VivoCell Metabolism, 2012
- ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effectNature, 2012
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Alterations of metabolic genes and metabolites in cancerSeminars in Cell & Developmental Biology, 2012
- Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic TherapyClinical Cancer Research, 2011
- Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1Cell, 2011
- Regulation of cancer cell metabolismNature Reviews Cancer, 2011
- Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progressionProceedings of the National Academy of Sciences, 2010
- MYC-Induced Cancer Cell Energy Metabolism and Therapeutic OpportunitiesClinical Cancer Research, 2009
- LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancerMolecular Cancer Therapeutics, 2009